IMUGENE CHART. TA only, page-26076

First 26076 Last

Share
Profile

Follow
godiva

1,557 Posts.

403

08/11/23

08:34

Post #: 70777381
Share

Originally posted by Eaglenebula: ↑

Hi
CR implies there is no visible disease on a scan. It is not exactly the same as a cure. People can have a CR and then have the disease come back again. There could be a small amount of residual disease that is below the ability of the scan to detect it. It could also be completely resolved. Time will tell. That patient will have more scans. It is very unlikely to be due to other factors. It is impossible to know what proportion of patients will have a CR until they run the full trial as the numbers are too small in this preliminary trial.

The other results are also great. You can imagine having your cancer partially go away or not get worse would be greatly appreciated in someone who has exhausted all other treatment options. Some of these patients could go on to have a CR or may have a significant period where the disease does not progress. Even small gains in this setting are helpful. An average increase in survival of a few months is considered a good result. Particularly in this setting. This would be appreciated by doctors and patients and be useful clinically.

As imu are claiming it is an impressive early result in a group of cancers that are the hardest to treat and with varying treatment doses which have not yet been optimized. Exactly how good we won’t know until the full trials are run but there is plenty of reason for optimism.

Expand

Not maximum dose as well, so results could have been even
better with higher.

IMU Price at posting: 6.6¢ Sentiment: Buy Disclosure: Held
5 Upvote

0 Great analysis

Reply

Top Stories

MSB

Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%

OCC

Orthocell shares jump on record revenues from sales of collagen bone repair devices globally

SRL

Scandium a priority metal for Sunrise as it plans feasibility update at Syerston

SPR

Spartan sniffs 126g/t gold ahead of resource upgrades at WA's Dalgaranga

PL3

Patagonia looks to raise $2.15M for South American exploration and development

There are more pages in this discussion • 7,295 more messages in this thread...

First 26076 Last

Add IMU (ASX) to my watchlist

(20min delay)
Last 5.1¢		Change 0.001(2.00%)		Mkt cap ! $374.8M

Open	High	Low	Value	Volume
5.0¢	5.2¢	4.9¢	$541.6K	10.76M

Buyers (Bids)

No.	Vol.	Price($)
8	818590	5.0¢

Sellers (Offers)

Price($)	Vol.	No.
5.1¢	249636	1

View Market Depth

No.	Vol.	Price($)
7	618590	0.050
40	5683742	0.049
27	1923707	0.048
12	1004292	0.047
17	975390	0.046

Price($)	Vol.	No.
0.051	249636	1
0.052	3008410	14
0.053	1998507	7
0.054	1087199	6
0.055	1401256	13

Last trade - 16.10pm 09/07/2024 (20 minute delay)

IMU (ASX) Chart

IMUGENE CHART. TA only, page-26076

Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%

Orthocell shares jump on record revenues from sales of collagen bone repair devices globally

Scandium a priority metal for Sunrise as it plans feasibility update at Syerston

Spartan sniffs 126g/t gold ahead of resource upgrades at WA's Dalgaranga

Patagonia looks to raise $2.15M for South American exploration and development

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

IMUGENE CHART. TA only, page-26076

Top Stories

Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%

Orthocell shares jump on record revenues from sales of collagen bone repair devices globally

Scandium a priority metal for Sunrise as it plans feasibility update at Syerston

Spartan sniffs 126g/t gold ahead of resource upgrades at WA's Dalgaranga

Patagonia looks to raise $2.15M for South American exploration and development

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News